Dr. Mukesh Kumar D. Delvadiya, MD

Dr. Delvadiya practices at Texas Oncology PA in Frisco, Texas.

Dr. Delvadiya's NPI, 1003070004, was assigned on July 18, 2008. Dr. Delvadiya graduated from B. J. Medical College Ahmedabad in 1991. Dr. Delvadiya holds Texas license P2430.

Dr. Delvadiya's primary practice is Texas Oncology PA, at 5858 Main St, Frisco, TX 75033 in Denton County. The practice phone is (972) 997-8000.

Dr. Delvadiya's primary practice is Texas Oncology PA in Frisco, Texas. Dr. Delvadiya is also affiliated with Texas Health Hospital Frisco. The medical group on file is Texas Oncology. Dmand AI also links Dr. Delvadiya to 3 more hospitals, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Delvadiya practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Delvadiya's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Delvadiya is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Delvadiya's licenses on file in 4 states: Texas, District of Columbia, Maryland and Virginia.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Delvadiya treats.

CMS data shows 15,371 Medicare services from Dr. Delvadiya across 37 procedure codes in 2024, for 304 Medicare patients. Medicare paid $237,250 for them.

CMS counts 304 Medicare patients who saw Dr. Delvadiya in 2024. The largest group is 75 to 84, with 138 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Delvadiya's median patient age at 58, with 64% women.

In 2024, Dr. Delvadiya wrote 945 Medicare Part D claims for 149 patients. 67% of them were for generic drugs. CMS names the drug for 678 of them, across 25 drugs with 11 or more claims each, at $1,563,996 in total drug cost. In 2023, CMS named 535 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Delvadiya for performance year 2024, reported through an alternative payment model (APM). Dr. Delvadiya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Delvadiya as offering telehealth.

Dmand AI links Dr. Delvadiya to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 581 general payments to Dr. Delvadiya from 66 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 61% of the total. Janssen Pharmaceuticals, Inc paid the most, $3,832.

Dr. Delvadiya graduated from B. J. Medical College Ahmedabad in 1991.

Dr. Delvadiya is in network with 22 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.